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Abstract 
Motor neurone disease (MND) is a disabling and ultimately fatal disease of the motor 
system, with unfortunately few effective treatments.  Considerable heterogeneity is 
observed in the clinical motor features of MND, with extra-motor manifestations now also 
recognized as part of the condition. Diagnosis remains clinical, with appropriate 
investigations to exclude mimics. The multidisciplinary team approach is at the centre of 
holistic management of patients and families and can improve both survival and quality of 
life. Although the disease remains incurable, a survival benefit has been observed with the 
use of non-invasive ventilation and riluzole. Recent identification of genetic causes of MND, 
particular the C9ORF72 hexanucleotide repeat expansion, adds to the expanding knowledge 
regarding aetiology and pathogenesis. However, the challenge to elucidate underlying 
causes of MND and establish effective disease-modifying therapies continues through 
active research. We provide a comprehensive review of MND, focusing on clinical features, 
diagnosis and management. 
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Motor neurone disease (MND) is a disabling and ultimately fatal neurodegerative disease. 
Progressive paralysis and muscle atrophy occur following degeneration of corticospinal 
upper motor neurones (UMNs), and spinal cord and brainstem lower motor neurones 
(LMNs), with eventual death from respiratory failure. 
 
Epidemiology 
The lifetime risk of MND in the UK is 1 in 472 women and higher - 1 in 350, in men.  The 
median survival is only 20-48 months (1) meaning there are only approximately 5000 
cases in the UK at any one time. (2)  Incidence is highest in 55Ȃ75-year olds and onset 
below the age of 40 years uncommon. (2) 
Aetiology and pathogenesis 
MND is thought to be caused by a complex interplay between genetic and exogenous 
factors.  Pathogenic mechanisms to which motor neurones are particularly vulnerable such 
as oxidative stress, glutamate excitotoxicity, and mitochondrial dysfunction are potential 
targets for new therapies. 5Ȃ10% of patients have a family history of MND, but recently, a 
C9ORF72 gene mutation (a hexanucleotide expansion repeat sequence in an intronic region 
of the gene) has been found in population studies to be present in 12-46% of cases with a 
family history and approximately 7-23% of sporadic cases. (3-5) This expansion has been 
associated with other neurodegenerative diseases: in particular fronto-temporal dementia ǯǤ (3-5) 
Classification 
MND can be classified into four main clinical phenotypes (Table 1). 
 
Presenting symptoms 
The most common presentation is of painless, often distal and asymmetrical weakness, 
wasting or fasciculation of limb muscles.  Whilst the disease is relentlessly progressive, 
patients may report fluctuations due to fatigue or loss of compensatory strategies. 
 
Lower limb onset causes difficulty in walking, unsteadiness, stiffness or foot-drop. 
Upper limb onset causes loss of functional hand dexterity, poor grip or proximal arm 
weakness.  
Bulbar-onset MND can present with change in the quality or volume of voice, dysphagia or 
excessive salivation. 
Respiratory-onset MND is uncommon. Symptoms include breathlessness, orthopnoea or 
hypercapnic features from overnight hypoventilation such as morning headaches, daytime 
somnolence or loss of appetite. 
 
Extra-motor manifestations of MND are becoming increasingly recognised: overt fronto-
temporal dementia affects approximately 5% of patients with a larger number 
experiencing minor cognitive difficulties or emotional lability and a small number having 
Parkinsonism. (6) Atypical findings such as sensory features, eye movement abnormalities, 
severe pain and sphincter involvement may suggest an alternative diagnosis. 
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Examination 
Clinical signs on examination are frequently more widespread than the symptoms and the 
presence of UMN and LMN in the same area is suggestive of MND. UMN signs may include 
increased tone, brisk reflexes and extensor plantar responses. LMN signs include muscle 
wasting, fasciculations, reduced or absent reflexes.  Examination of the small muscles of the 
hands may reveal early wasting of the first dorsal interossei and finger extensors with 
preserved finger flexion. (Figure 1)  Bulbar findings include dysarthria and dysphonia, 
tongue weakness, wasting or fasciculations (LMN).  Tongue spasticity, brisk jaw jerk and 
emotional lability suggest UMN pseudobulbar palsy.   
 
Assessment should also note ǯǡ 
cough, swallow and respiratory function with bedside testing including force vital capacity 
(FVC), transdermal arterial oxygen and carbon dioxide levels and the Edinburgh Cognitive 
and Behavioural ALS Screen (ECAS). 
 
Making the diagnosis 
Diagnosis remains clinical, using investigations to exclude mimics. Patients may present to 
other specialties including orthopaedics, ENT and respiratory medicine: identification of 
neurological signs may be a clue to the diagnosis.  Mimics affecting the LMN include 
mononeuritis multiplex, chronic inflammatory demyelinating polyneuropathy, multifocal 
motor neuropathy with conduction block, nerve entrapment disorders, spinal muscular 
atrophy and post-polio syndrome.   The X-linked disorder Kennedy's syndrome, caused by 
a trinucleotide repeat expansion in the androgen receptor gene, and has a better prognosis 
than MND with a slower, LMN spinal and bulbar disease, which may be associated with 
diabetes, gynaecomastia and testicular atrophy. 
 
Muscle disorders should be considered, particularly inclusion body myositis, which causes 
asymmetrical weakness and wasting, although, in contrast to the typical pattern of 
weakness in MND, the quadriceps and finger flexors are characteristically involved. The 
non-progressive benign crampȂfasciculation syndrome presents with isolated cramps and 
fasciculations without other neurological signs.  Structural, infective or inflammatory 
intracranial or spinal pathology and hereditary spastic paraparesis cause pure UMN signs 
whereas cervical radiculomyelopathy, syringomyelia/-bulbia and dual pathologies can 
present with mixed UMN and LMN signs.  Brainstem or oropharyngeal lesions, myasthenia 
gravis and oculopharyngeal muscular dystrophy should be considered in bulbar 
presentations. 
 
Investigations 
Nerve conduction studies and electromyography can identify LMN pathology and muscle 
disorders whilst magnetic resonance imaging of the brain and spine is indicated with 
clinical UMN signs.   Blood tests should exclude hyperthyroidism, hyperparathyroidism, 
HIV and Lyme disease and lumbar puncture should be considered in atypical cases to 
exclude inflammatory or infiltrative disease. Genetic testing should be considered to 
diagnose Kennedy's syndrome and those with MND with relevant clinical features (such as 
young onset, or with features of, or a family history of neurodegenerative disorders).  Next-
generation sequencing of a panel of genes can aid diagnosis, but genetic counseling should 
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be considered given the impact of the diagnosis on the family and potential family planning 
options such as pre-implantation diagnosis. 
 
Giving the diagnosis 
Sensitive delivery of the diagnosis of MND, combining honesty without destruction of hope, 
can have a positive impact on patients.  The doctor should explain the incurable nature of 
the disease, its variable but unpredictable prognosis and a positive emphasis on the 
treatment and support available, including the role of the multidisciplinary team (MDT). 
Early and ongoing follow-up should be arranged with the hospital and community MDT. 
 
Management 
 
Multidisciplinary team 
Care by a specialist MND teams is associated with a better survival and quality of life (7).  
The team should include nurse specialists, physiotherapists, occupational, speech and 
language therapists and dieticians, whilst involvement from respiratory medicine, 
gastroenterology and palliative care may be required later in the disease course. The Motor 
Neurone Disease Association charity provides support to patients and families in the UK.  
Along with symptom management and psychosocial support, access to mobility and 
communication aids, social care and financial assistance is vital.  
 
Respiratory support 
Respiratory failure is often insidious and presents with symptoms of daytime somnolence, 
disturbed sleep, morning headaches, loss of appetite or reduced exercise tolerance.  Loss of 
cough and bulbar function can result in aspiration and pneumonia and is a common cause 
of death.  Use of non-invasive ventilation (NIV) improves survival by an average of 7 
months with preserved quality of life (8) whilst physiotherapy, cough assist devices, 
nebulisers and suction machines can aid mucous clearance.  A recent UK study found that 
diaphragmatic pacing as an adjunct to NIV appeared detrimental and was associated with 
shorter survival. (9) 
 
Nutritional support 
Weight loss, choking episodes, aspiration and tiring at mealtimes may indicate the need for 
supplementary feeding. Percutaneous endoscopic gastrostomy (PEG) insertion can be 
adapted for frailer patients or those with respiratory failure in whom the procedure 
presents a higher risk (10). Options should be discussed early, as evidence suggests that 
the best outcomes are achieved if PEG insertion occurs before major loss of body weight or 
marked deterioration in respiratory function. (10) 
 
Pharmacological treatments 
 Riluzole is the only drug licensed for treatment of the ALS form of MND and modestly 
prolongs median survival by approximately 3 months. (11) Trials of other multiple other 
potential neuroprotective agents such as lithium and dexpramipexole have failed to show 
benefit. 
  
 6 
Symptomatic therapies: the MDT approach to symptoms usually involves both 
pharmacological and non-pharmacological strategies.  Table 2 
 
Prognosis 
The median survival for ALS is 20-48 months, but 10% of patients with ALS live longer than 
10 years and patients with primary lateral sclerosis may have a normal life expectancy. (1)  
Poor prognostic indicators include older age and bulbar- or respiratory-onset. Patients may 
wish to discuss end-of-life issues and make advanced directives at any time in the disease. 
 
Conclusion 
As research continues to advance our understanding of MND pathogenesis, identification of 
new therapeutic targets will assist in creating novel treatments, with the ultimate goal of 
arresting the progression of MND.  In the meantime, the holistic MDT approach has 
improved survival and quality of life of patients and carers living with the disease. 
 
 
Key points 
 
x MND is an uncommon neurodegenerative disease with a variable phenotype 
x There are approximately 5 000 people in the UK with MND, peak onset being 55-75 
years  
x It has a highly variable clinical course, but a median survival of 20-48 months 
x Limb-onset amyotrophic lateral sclerosis, with mixed upper motor neurone and 
lower motor neurone signs, is the most common type 
x Diagnosis is clinical, with exclusion of mimics using appropriate investigations 
x Management requires a multidisciplinary approach, which can improve survival and 
quality of life 
x Riluzole and non-invasive ventilation also improve survival. 
x Whilst familial disease is uncommon, advances in understanding the genetics of 
MND have been made, with expansions in the C9ORF72 gene now being commonest 
identified genetic abnormality, occurring in 10% of all cases of MND. 
x There is an increasingly recognised overlap with other neurodegenerative 
conditions with some patients displaying features fronto-temporal dementia and 
Parkinsonism. 
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Table 1 
 
Clinical phenotypes of motor neurone disease 
 
 
Phenotype Features 
Amyotrophic 
lateral 
sclerosis 
(ALS) 
75% of all cases 
Limb onset with mixed UMN and LMN clinical features 
Average survival 2-5 years  
Men >women (3:2) 
Progressive 
bulbar palsy 
(PBP) 
20% of all cases  
Bulbar (LMN) and/or pseudobulbar (UMN) palsy 
onset 
Poorer prognosis  
Progressive 
muscular 
atrophy 
(PMA) 
5% of cases 
Pure LMN signs at onset, may develop UMN signs later 
Men>>women (5:1), onset commonly <50 years old 
May be associated with slower disease progression 
Primary 
lateral 
sclerosis (PLS) 
Pure UMN signs at onset at onset, lower limbs often 
affected first 
0.5% of cases 50% progress to ALS phenotype 
Median onset 50 years old 
Better prognosis, may have normal life expectancy 
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Table 2 
 
Symptomatic therapies in motor neurone disease 
 
Symptoms Pharmacological therapy Notes 
Cramps and 
fasciculations 
Quinine 200±300 mg at night Titrate doses to response 
Carbamazepine start at 100 mg daily   
Spasticity Baclofen start at 5 mg bd-tds Cautious titration: low tone may worsen 
mobility 
Dantrolene start at 25 mg daily Treat worsening factors e.g. pain, constipation 
Tizanidine start at 2 mg daily Physiotherapy 
Excessive 
saliva 
Hyoscine patch 0.5±1 mg every 3 days Suction machines 
Amitriptyline start at 10 mg at night In severe cases botulinum toxin to salivary glands or hyoscine syringe driver  
Atropine 1% eye drops bd-tds Thining saliva may worsen thick respiratory 
secretions  
Poor cough 
/respiratory 
secretions 
Carbocysteine 250±750 mg tds Cough-assist and suction devices 
Nebulised saline Adequate fluid intake 
Emotional 
lability 
SSRIs (e.g. citalopram 10mg) Psychological support 
Amitriptyline start at 10 mg at night Educate about cause of symptoms 
Constipation Lactulose / docusate / movicol Review drug adverse effects 
  Check adequate fluid and fibre intake 
Dyspnoea Oral morphine start at 2.5 mg 6-hourly Pre-emptive palliative prescribing 
Nebulised morphine 5 mg Increase use of NIV 
Lorazepam sublingual 0.5±2 mg Address anxiety and fears 
Diamorphine in late stages Attention to sleeping position 
Paroxysmal 
choking/ 
laryngospasm 
Lorazepam sublingual 0.5±2 mg Careful positioning 
  
Suction/NIV may help 
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SSRIs, selective serotonin reuptake inhibitors; NIV, non-invasive ventilation. 
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